BRCA1 Protein
-
Subject Areas on Research
- A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1.
- A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
- An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
- BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
- BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
- BRCA1 expression is not directly responsive to estrogen.
- BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
- BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function.
- BRCA1 mutations in primary breast and ovarian carcinomas.
- Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.
- Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
- Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
- CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
- Cell cycle control of BRCA2.
- Charting the landscape of tandem BRCT domain-mediated protein interactions.
- Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
- Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
- Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.
- Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
- Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
- Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.
- Development of human protein reference database as an initial platform for approaching systems biology in humans.
- Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
- Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
- Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.
- Genetic/familial high-risk assessment: breast and ovarian.
- Germline Genetic Testing: What the Breast Surgeon Needs to Know.
- Human ovarian cancer of the surface epithelium.
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
- Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers.
- Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
- Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
- Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
- Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer.
- Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
- Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation.
- Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage.
- Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair.
- Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.
- Managing hereditary ovarian cancer risk.
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
- Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
- Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2.
- Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
- Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway.
- Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation.
- Pilot study of rapid MR pancreas screening for patients with BRCA mutation.
- Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science.
- Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing.
- Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
- Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.
- Refining the role of BRCA1 in combating oxidative stress.
- Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha.
- Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding.
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
- Risk factors for ovarian cancers with and without microsatellite instability.
- Screening for the breast cancer gene (BRCA1) using a biochip system and molecular beacon probes immobilized on solid surfaces.
- Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks.
- Surface-enhanced Raman scattering substrate based on a self-assembled monolayer for use in gene diagnostics.
- Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
- Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
- The genetic attributable risk of breast and ovarian cancer.
- Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
- Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
- Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute